Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSR149415 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| SSR149415 - 250 mg | EXPERIMENTAL | SSR149415 250 mg, twice daily for a maximum of 8 weeks |
| SSR149415 - 100 mg | EXPERIMENTAL | SSR149415 100 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks |
| Paroxetine | ACTIVE_COMPARATOR | Paroxetine 20 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo for a maximum of 9 weeks |
| Name | Type | Description |
|---|---|---|
| SSR149415 | DRUG | - |
| Placebo | DRUG | Oral administration (capsules) |
| Paroxetine | DRUG | Oral administration (capsules) |
Inclusion Criteria: * Diagnosis of major depressive disorder, recurrent, as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) criteria (296.3) and confirmed by the semi-structured Mini International Neuropsychiatric Interview (MINI) Exclusion ...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Definium Therapeutics, Inc. | DFTX | 2 | PHASE3 | DT120 |
| Vistagen Therapeutics, Inc. | VTGN | 3 | PHASE3 | Fasedienol |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | VQW-765 |
| AbbVie, Inc. | ABBV | 1 | PHASE2 | ABBV-932 |
| Psyence Biomedical Ltd. | PBM | 1 | PHASE2 | Psilocybin therapy |
SSR149415 is an investigational small molecule being developed by Sanofi for the treatment of Depressive Disorder and Anxiety Disorders, specifically studied in patients with Major Depressive Disorder and Generalized Anxiety Disorder. It has been evaluated in Phase 2 clinical trials.
SSR149415 is being developed by Sanofi, a multinational pharmaceutical company traded on the stock exchange under the ticker SNY. The drug is an investigational small molecule in the psychiatry therapeutic area, targeting depressive and anxiety disorders.
SSR149415 is in Phase 2 clinical development. It has completed three Phase 2 trials, two in Major Depressive Disorder and one in Generalized Anxiety Disorder. The drug is investigational and not yet approved by regulatory authorities.
SSR149415 has completed three Phase 2 trials: NCT00358631 and NCT00361491 in Major Depressive Disorder, and NCT00374166 in Generalized Anxiety Disorder. These trials were randomized, double-blind, and placebo-controlled, with a combined enrollment of 968 patients across multiple countries.
SSR149415 is the primary identifier for this investigational compound. No alternative names have been reported in the clinical trial data, and it is distinct from other marketed psychiatric medications. It is a small molecule developed by Sanofi for depressive and anxiety disorders.